Celcuity Insider Deals: Owner NIGON RICHARD Sells $107‑Valued Shares Amid Bull‑Run Buzz, Raising Questions About Stock’s Fragile Momentum

Insider Selling in a Bull‑Run: What Celcuity’s Recent Deal Signals

Celcuity Inc. (NASDAQ: CELC) finished the year on a high note, with its shares trading at $104.67—about 92 % of the 52‑week high. Yet on December 15, 2025, owner NIGON RICHARD sold 19,975 shares at no disclosed price, reducing his stake to 89,035 shares. The transaction, filed under Form 4, occurred during a period of heightened social‑media buzz (170 % intensity) and a modest 0.03 % price lift, suggesting a tactical move rather than a panic sale.

Investor Takeaway: Volatility, Valuation, and Timing

Celcuity’s price‑to‑earnings ratio of –30.05 and price‑to‑book of 39.78 reflect a company still generating negative earnings amid rapid share price growth. The recent sell‑off by a major insider may reinforce concerns that the stock’s upward momentum is fragile. For investors, this could be a signal to reassess risk exposure: either lock in gains or re‑enter cautiously at lower support levels, especially if the company’s clinical pipeline stalls.

NIGON RICHARD: A Pattern of Opportunistic Trading

Reviewing Richard’s transaction history paints the picture of an insider who buys when the stock is undervalued and sells when it reaches short‑term highs. In September 2025, he purchased 4,672 and 3,245 shares at $7.56 each, simultaneously liquidating the same number of warrants. His most recent sale on December 15 coincided with a price near $107, suggesting a disciplined exit strategy. The pattern indicates a focus on capital preservation rather than long‑term holding, which may influence how other insiders view their own positions.

Broader Insider Activity: A Mixed Bag

While Richard’s sale stands out, other insiders have shown contrasting behavior. CEO Sullivan B. F. added 104,340 shares in early September, and CFO Vicky Hahne bought 80,000 options in August. This divergence hints at internal confidence in the company’s growth trajectory, yet the simultaneous selling by Richard introduces an element of uncertainty. Analysts should monitor whether other insiders follow Richard’s lead or maintain their bullish stance.

The Road Ahead: What’s Next for Celcuity?

Celcuity’s clinical pipeline remains its primary value driver. If upcoming trial data corroborate the company’s therapeutic claims, insider confidence may return, potentially spurring a new buying wave. Conversely, any setback could trigger a cascade of sell‑offs, exacerbating the current valuation disconnect. Investors should stay alert to both insider filings and clinical milestones, using the December sale as a benchmark for future price action.